Veru to Participate in the Virtual BTIG Obesity Health Forum
- MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the company will be participating in one-on-one meetings and a fire side chat presentation with investors at the virtual BTIG Obesity Health Forum on June 18, 2025.
- 06/11/2025
|
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
- --Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program-- -- Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (Diarrhea, Nausea, and GERD) compared to semaglutide alone--
- 05/28/2025
|
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
- Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces lean mass loss by 99%, preserves physical function, and enhances selective fat loss when combined with semaglutide (Wegovy). VERU's lean balance sheet, with $20 million in cash and no debt, positions it favorably to take advantage of near-term catalysts.
- 05/26/2025
|
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript
- Veru Inc. (NASDAQ:VERU ) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Anthea Li - Jefferies Gary Nachman - Raymond James William Wood - B. Riley Securities Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to Veru Inc.'s Investor Conference Call.
- 05/08/2025
|
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level
- Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D.
- 05/08/2025
|
Veru Participates in a Virtual Investor KOL Connect Segment
- -- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP.
- 05/08/2025
|
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
- --Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 --
- 05/08/2025
|
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
- MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update.
- 05/01/2025
|
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
- MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the Company will present at the 2nd Annual GLP-1-Based Therapeutics Summit, taking place April 29 - May 1, 2025, in Boston, Massachusetts.
- 04/16/2025
|
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
- MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Jones Healthcare and Technology Innovation Conference, in Las Vegas, Nevada, on April 9, 2025 at 3:00 pm – 3:20 pm Pacific Daylight Time.
- 03/31/2025
|
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 03/06/2025
|
Veru Inc (VERU) Q1 2025 Earnings Call Transcript
- Veru Inc (NASDAQ:VERU ) Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications. Mitchell Steiner - Chairman, Chief Executive Officer and President Michelle Greco - CFO and CAO Gary Barnette - Chief Scientific Officer Conference Call Participants William Wood - B.
- 02/13/2025
|
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
- --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function-- -- The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed--
- 02/13/2025
|
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
- Veru Inc. VERU stock is plummeting on Monday after the company released topline results from the Phase 2b QUALITY clinical study of enobosarm for weight reduction.
- 01/27/2025
|
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
- -- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less lean mass than patients receiving WEGOVY alone --
- 01/27/2025
|
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?
- Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/23/2025
|
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
- MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm as well as other co-investors, for $18 million, subject to adjustment as set forth in the purchase agreement.
- 12/31/2024
|
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
- Veru Inc. (VERU) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago.
- 12/16/2024
|
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
- MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders, taking place December 6-8, 2024, in Washington, DC.
- 11/26/2024
|
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
- MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
- 11/05/2024
|
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
- MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas.
- 10/21/2024
|
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
- MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the World Obesity and Weight Management Congress, taking place October 24-26, 2024, in Baltimore, Maryland.
- 10/16/2024
|
Veru to Present at the 2024 Cantor Global Healthcare Conference
- MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present a corporate update with a focus on the progress of Veru's Phase 2b clinical development program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM – 2:25 PM Eastern Time.
- 09/11/2024
|
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
- Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies William Wood - B. Riley Securities Gary Nachman - Raymond James Leland Gershell - Oppenheimer Yi Chen - H.C.
- 08/10/2024
|
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
- Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.
- 08/08/2024
|
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
- --Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected January 2025--
- 08/08/2024
|
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
- MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and to provide a business update.
- 08/01/2024
|
Veru to Participate in the BTIG Virtual Biotechnology Conference
- MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in one-on-one meetings with investors at the BTIG Virtual Biotechnology Conference on August 5th, 2024.
- 07/29/2024
|
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
- MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts.
- 07/02/2024
|
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
- MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.
- 06/24/2024
|
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
- MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that its Annual Meeting of Shareholders scheduled for today (Annual Meeting) was convened and adjourned without any business being conducted due to lack of a required quorum.
- 06/18/2024
|
Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders
- MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remind shareholders to vote in connection with the Company's upcoming annual meeting of shareholders, to be held on Tuesday, June 18, 2024, at 9:00 AM ET. Shareholders are advised to vote their shares in advance of the proxy voting deadline of tomorrow, Tuesday, June 18, 2024, at 9:00 AM ET.
- 06/17/2024
|
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
- MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.
- 06/10/2024
|
Veru to Present at the Jefferies Global Healthcare Conference
- MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru's Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am – 11:25 am ET.
- 05/22/2024
|
Veru Announces Steven B. Heymsfield M.D.
- MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator for the Company's Phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA for weight loss.
- 05/15/2024
|
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
- MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer, will be a Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week, taking place May 21-23, 2024, in Tel Aviv, Israel.
- 05/14/2024
|
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
- --Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise--
- 05/08/2024
|
Veru to Present at the GLP-1 Based Therapeutics Summit
- MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA.
- 05/02/2024
|
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
- MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update.
- 05/01/2024
|
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
- Veru Inc. (VERU) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VERU's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
- 04/30/2024
|
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
- -- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 --
- 04/30/2024
|
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
- MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.
- 04/25/2024
|
What Makes Veru (VERU) a New Buy Stock
- Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/17/2024
|
Veru Reschedules Annual Meeting of Shareholders
- --Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings--
- 03/22/2024
|
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
- MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug for potentially higher quality weight loss.
- 03/12/2024
|
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
- MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on February 21, 2024 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).
- 02/27/2024
|
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
- MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the formation of a new Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for potentially higher quality weight loss. The Scientific Advisory Board brings deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical research and in drug development.
- 02/20/2024
|
The 3 Best Penny Stocks to Buy in February 2024
- Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of companies that make life in the financial markets, we can always identify good investment opportunities that allow us to add value to our portfolio and our wealth.
- 02/15/2024
|
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
- The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 02/13/2024
|
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
- Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
- 02/08/2024
|
Veru Reports Fiscal 2024 First Quarter Financial Highlights
- —Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone—
- 02/08/2024
|
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
- FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone
- 02/06/2024
|
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/01/2024
|
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru's Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the upcoming virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 12:40 pm – 1:10 pm ET.
- 01/31/2024
|
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
- MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, February 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 first quarter financial results and to provide a business update.
- 01/25/2024
|
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
- MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference to be held at the InterContinental New York, Barclay Hotel in New York City on September 28th, 2023 at 10:55 a.m. ET.
- 09/20/2023
|
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
- MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the H.C. Wainwright 25th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, September 11th, 2023 at 9:00 a.m. ET.
- 08/30/2023
|
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
- Veru Inc. (VERU) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.28 per share a year ago.
- 08/10/2023
|
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
- MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute respiratory distress syndrome (ARDS), today announced it will host a conference call and audio webcast on Thursday, August 10, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 third quarter financial results and to provide a business update.
- 08/03/2023
|
Veru to Present at the Jefferies Healthcare Conference
- MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 11 a.m. ET.
- 05/24/2023
|
Veru Inc. (VERU) Q1 2023 Earnings Call Transcript
- Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & President Michele Greco - Chief Financial Officer & Chief Accounting Officer Conference Call Participants Yi Chen - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Operator Good morning, ladies and gentlemen, and welcome to Veru Inc. Investor Conference Call.
- 05/11/2023
|
Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates
- Veru Inc. (VERU) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.18 per share a year ago.
- 05/11/2023
|
VERU Stock Earnings: Veru Misses EPS, Beats Revenue Estimates
- Veru (NASDAQ: VERU ) just reported its fiscal second-quarter results. Veru reported a loss per share of 43 cents.
- 05/11/2023
|
Is a Surprise Coming for Veru (VERU) This Earnings Season?
- Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/09/2023
|
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
- MIAMI, FL, April 27, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced it will host a conference call and audio webcast on Thursday, May 11, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 second quarter financial results and provide a business update.
- 04/27/2023
|
Advanced Penny Stocks Research Methods
- Can these top tips help your penny stocks trading? The post Advanced Penny Stocks Research Methods appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/23/2023
|
Why Is VERU Stock Up 3% Today?
- Veru (NASDAQ: VERU ) stock is getting a boost on Friday after the company revealed plans to sell its ENTADFI capsule business. That sale has the company agreeing to sell the business for $20 million to Blue Water Vaccines (NASDAQ: BWV ).
- 04/21/2023
|
Top 5 Defensive Stocks That Are Set To Fly
- The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
- 03/24/2023
|
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
- MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12 pm ET.
- 03/07/2023
|
Why Is Veru (VERU) Stock Down 37% Today?
- Veru (NASDAQ: VERU ) stock is taking a beating on Friday after the FDA denied the company's request for EUA for its Covid-19 treatment. That rejection has to do with sabizabulin, which is Veru's drug for treating patients in hospitals suffering from severe Covid-19.
- 03/03/2023
|
Veru stock plummets toward 2 1/2-year low after FDA denies EUA request for COVID-19 treatment
- Share of Veru Inc. VERU, +0.53% plunged 31.0% toward a 2 1/2-year low in premarket Friday, after the U.S. Food and Drug Administration turned down the biopharmaceutical company's request for Emergency Use Authorization (EUA) for sabizabulin, its treatment for hospitalized patients with COVID-19 who are at high risk for Acute Respiratory Distress Syndrome (ARDS). The company said that although the FDA declined the EUA request, “the FDA remains committed to working with the company for the development of sabizabulin.
- 03/03/2023
|
Veru Inc.: Q1 Revenues Fall Short And Uncertainty Looms, Making It Risky
- Veru Inc. is eyeing emergency use authorization for its COVID-19 drug Sabizabulin, which is currently under FDA review. Veru Inc. shares fell around 20% to a 52-week low after reporting Q1 FY23 results that fell short of analysts' revenue forecasts.
- 02/27/2023
|
Veru Inc. (VERU) Q1 2023 Earnings Call Transcript
- Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call February 9, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & President Michele Greco - Chief Financial Officer & Chief Accounting Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Leland Gershell - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Veru Inc. Investor Conference Call.
- 02/09/2023
|
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
- Veru Inc. (VERU) delivered earnings and revenue surprises of -21.05% and 50.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/09/2023
|
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
- MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Thursday, February 9, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 first quarter financial results and provide a business update.
- 01/26/2023
|
Why Is VERU Stock Up 8% Today?
- One of last year's surprise hits in the biotech sphere, Veru (NASDAQ: VERU ) is making headlines once again today. Currently, VERU stock is up 8%.
- 01/10/2023
|
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
- Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
- 12/13/2022
|
Is There any Hope for Veru Stock?
- The near term looks bad, and it might take a while to get better.
- 12/10/2022
|
Veru Inc. (VERU) Q4 2022 Earnings Call Transcript
- Veru Inc. (NASDAQ:VERU ) Q4 2022 Earnings Conference Call December 5, 2022 8:00 AM ET Company Participants Brandon Folkes - Cantor Fitzgerald Leland Gershell - Oppenheimer Chris Howerton - Jefferies Yi Chen - H.C. Wainwright Conference Call Participants Sam Fisch - Executive Director, Investor Relations, and Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer and President Michele Greco - Chief Financial Officer and Chief Administrative Officer Operator Good morning ladies and gentlemen, and welcome to Veru Inc.'s Investor Conference Call.
- 12/05/2022
|
Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates
- Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 12/05/2022
|
Is Veru a Buy?
- Or is it just another risky COVID stock?
- 12/02/2022
|
Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
- MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Monday, December 5, 2022, at 8:00 a.m. ET to discuss its fiscal 2022 fourth quarter and full year ended September 30, 2022 financial results and provide a business update.
- 11/28/2022
|
Is It Too Late to Buy Veru Stock?
- The negative impact of its COVID-19 program faltering will soon be in the past.
- 11/23/2022
|
Why Shares of Veru Fell 10.33% on Monday
- Investors are concerned that approval for a COVID-19 therapy will be delayed or denied.
- 11/21/2022
|
Why Veru Stock Was Losing One-Third of Its Value This Week
- The future of a top pipeline drug now looks much dimmer.
- 11/11/2022
|
Why Veru Stock Is Cratering Today
- A negative vote on one of its drugs is weighing on the biotech's stock price.
- 11/10/2022
|
Why Is VERU Stock Down 50% Today?
- When a regulator hits the brakes on a drug's advancement, small businesses can buckle under the pressure. This seems to be happening with Veru (NASDAQ: VERU ) today as the Food and Drug Administration (FDA) denied an emergency use authorization (EUA) for Veru's proposed Covid-19 drug.
- 11/10/2022
|
Veru Stock Plummets 65% After FDA Advisors Vote Down Cancer-Turned-Covid Drug
- Veru stock collapsed Thursday after the FDA's advisors voted against the company's cancer drug turned Covid treatment. The post Veru Stock Plummets 65% After FDA Advisors Vote Down Cancer-Turned-Covid Drug appeared first on Investor's Business Daily.
- 11/10/2022
|
Strength Seen in Veru Inc. (VERU): Can Its 39.5% Jump Turn into More Strength?
- Veru Inc. (VERU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 11/08/2022
|
VERU Stock Soars 40% Despite Uncertainty Surrounding Covid-19 Drug
- Pharmaceutical firm Veru (NASDAQ: VERU ) kicked off the first complete week of November with a bang as it delivered overall positive results regarding its Covid-19 therapeutic sabizabulin. Targeting the treatment of Covid-19 for hospitalized patients at high risk of acute respiratory distress syndrome (ARDS), sabizabulin demonstrated effectiveness at reducing the death rate in a late-stage trial.
- 11/07/2022
|
Medical Leader Veru Catapults As FDA Preps To Discuss Cancer Drug For Covid
- Veru stock skyrocketed Monday after the Food and Drug Administration posted a mixed review of its repurposed cancer drug for Covid treatment. The post Medical Leader Veru Catapults As FDA Preps To Discuss Cancer Drug For Covid appeared first on Investor's Business Daily.
- 11/07/2022
|
Why Veru Stock Is Skyrocketing Today
- Investors are reacting positively to an FDA briefing document.
- 11/07/2022
|
Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
- MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that data from the Phase 3 trial of sabizabulin for hospitalized moderate to severe COVID-19 patients who required supplemental oxygen has been accepted as a late-breaker oral presentation at the upcoming IDWeek (Infectious Disease Week) 2022 taking place October 19-23, 2022, in Washington, D.C.
- 10/13/2022
|
2 Top Healthcare Stocks Defying the Bear Market
- Both companies have revenue rolling in today, and they both expect loads more in the near term.
- 10/09/2022
|
7 Momentum Stocks to Buy Now for Extraordinary Gains
- Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock or sector.
- 09/26/2022
|
Veru Inc.: A Very Complicated Tale
- Today, we put Veru Inc. in the spotlight for the first time. The stock fell over 20% trading Wednesday after the FDA stated it would require an AdComm Panel for the company's COVID-19 therapy sabizabulin prior to approval.
- 09/08/2022
|
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
- —Advisory Committee Meeting Scheduled for October 06, 2022— —Advisory Committee Meeting Scheduled for October 06, 2022—
- 09/07/2022
|
Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022
- MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available through the Conference on September 12, 2022, starting at 7:00 AM (Eastern Daylight Time).
- 09/06/2022
|
Got $1,500? Buy These 2 Surging Growth Stocks
- Their recent successes with commercializing medicines are paying off.
- 09/02/2022
|
Why Veru Stock Is Plunging Today
- A wave of profit-taking appears to be weighing on the biotech's shares today.
- 08/30/2022
|
This Growth Stock Has Soared Over 200% Year to Date -- Is It a Buy?
- More than two years into the pandemic, hospitalized patients with severe cases may get a game-changing treatment.
- 08/16/2022
|
Why Veru Stock Is Flying High Today
- Investors eagerly wait authorization of Veru's COVID-19 therapy.
- 08/11/2022
|
Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2022 Results - Earnings Call Transcript
- Veru Inc. (NASDAQ:VERU ) Q3 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director, IR & Corporate Communications Mitchell Steiner - Chairman, President & CEO Michele Greco - CFO & Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Leland Gershell - Oppenheimer Chris Howerton - Jefferies Yi Chen - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Veru Inc's Investor Conference Call.
- 08/11/2022
|
Why Is VERU Stock Up 36% Today?
- Source: Shutterstock Veru (NASDAQ: VERU ) stock is heading higher on Thursday as investors celebrate positive news in its earnings report for the fiscal third quarter of 2022. However, it's not the earnings report that is positive.
- 08/11/2022
|
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
- Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
Got $5,000? These 2 Stocks Are Crushing the Market This Year
- Can they continue outperforming the S&P?
- 08/10/2022
|
Veru: The Signs Seem To Point To An EUA For Sabizabulin
- Veru ought to find out very soon whether its lead asset, Sabizabulin, has been awarded an Emergency Use Authorization to treat hospitalized COVID patients. The company's share price leapt >$20 when its COVID study data was published, showing a clinically and statistically meaningful 55% relative reduction in deaths.
- 07/13/2022
|
Why Veru Stock Jumped Today
- The company is generously paying a few new hires.
- 07/13/2022
|
Why Veru Stock Soared 15% Higher on Monday
- One analyst enthusiastically reiterates his case for buying the stock.
- 07/11/2022
|
VERU's Shares Jump on Successful COVID-19 Study Results
- VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
- 07/08/2022
|
Why Veru Stock Trounced the Market on Thursday
- Several analysts reiterate their bullish outlook on the company.
- 07/07/2022
|
Jefferies Analyst Predicts FDA Emergency Use Nod For Veru's New COVID-19 Therapy In One Month
- Despite recent investor skepticism, the Phase 3 COVID-19 results for Veru Inc's (NASDAQ: VERU) sabizabulin published in the New England Journal of Medicine "addressed most concerns," Jefferies writes. The analyst sees the data as "further derisking.
- 07/07/2022
|
VERU Stock Pops on Clinical Trial Update
- Veru (VERU) stock is on the move Wednesday after the company published results from its Phase 3 clinical trial of sabizabulin. The post VERU Stock Pops on Clinical Trial Update appeared first on InvestorPlace.
- 07/06/2022
|
Why Veru Stock Is Popping Today
- It just published great-looking data from a phase 3 clinical trial for its antiviral treatment for severe COVID-19.
- 07/06/2022
|
Why Veru Stock Is Soaring
- Veru Inc (NASDAQ: VERU) shares are trading higher Wednesday after the company announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for.
- 07/06/2022
|
Why Veru Stock Surged Today
- The biotech's experimental oral COVID-19 treatment could be a game changer.
- 06/07/2022
|
Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment
- Veru Inc (NASDAQ: VERU) has submitted an emergency use authorization (EUA) for sabizabulin application to FDA for COVID-19 treatment. The application covers moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome (ARDS).
- 06/07/2022
|
Veru: On Right Track For FDA EUA Submission
- An Emergency Use Authorization submission of sabizabulin for high-risk hospitalized Covid-19 patients is expected Q2 of 2022. With EUA and then possibly NDA occurring for sabizabulin, Veru would be in a good position to develop advance purchase orders with several Government agencies around the world.
- 05/27/2022
|
Veru Inc. Still Has Serious Growth To Realize
- Veru Inc is a Florida-based drug developer, which focuses primarily on developing cancer-treatment drugs as well as its sexual health division. This year, the company hit a stroke of luck upon discovering its cancer treatment candidate, Sabizabulin is a highly efficacious and safe treatment against ARDS in later-stage Covid-19 patients.
- 05/19/2022
|
VERU Stock Alert: 6 Things to Know as Veru Appoints a New Executive
- Veru (VERU) stock is on the move Wednesday following news of the biopharmaceutical company adding Joel Batten to its list of executives. The post VERU Stock Alert: 6 Things to Know as Veru Appoints a New Executive appeared first on InvestorPlace.
- 05/18/2022
|
So What's Up With Veru Shares Rising Today?
- Shares of companies in the broader consumer staples sector, including Veru Inc (NASDAQ: VERU), are trading higher as stocks rebound from recent weakness. Stocks have experienced volatility this year amid Fed policy tightening measures.
- 05/17/2022
|
Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise
- VERU stock's rapid upward trajectory could continue as Veru releases its fiscal results and marks a significant clinical milestone. The post Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise appeared first on InvestorPlace.
- 05/17/2022
|
Veru: Where Big Pharma Failed To Tread
- Veru's Sabizabulin showed superlative results in critically ill COVID patients. No other drug has been able to achieve this.
- 05/17/2022
|
Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022
- MIAMI, May 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at the H.C. Wainwright Global Investment Conference. The presentation will be available through the Conference on Tuesday, May 24th at 11:30 AM – 12:00 PM (Eastern Daylight Time).
- 05/17/2022
|
5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated
- Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
- 05/16/2022
|
Veru Inc.'s (VERU) CEO Mitchell Steiner on Q2 2022 Results - Earnings Call Transcript
- Call End: Veru Inc. (NASDAQ:VERU ) Q2 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Chris Howerton - Jefferies Leland Gershell - Oppenheimer Yi Chen - H.C. Wainwright Kumar Raja - Brookline Capital Markets Operator Good morning, ladies and gentlemen, and welcome to Veru Incorporated Investor Conference Call.
- 05/12/2022
|
Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates
- Veru Inc. (VERU) delivered earnings and revenue surprises of -12.50% and 14.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
VERU Stock Pops on a Covid-19 Treatment Milestone
- Veru (VERU) stock is rising higher on Wednesday following a recent ruling from the FDA concerning the company's Covid-19 treatment. The post VERU Stock Pops on a Covid-19 Treatment Milestone appeared first on InvestorPlace.
- 05/11/2022
|
Best Stocks To Buy Now? 5 Health Care Stocks In Focus
- Could these health care stocks be the remedy to investors' recent stock market pains?
- 05/09/2022
|
Earnings Preview: Veru Inc. (VERU) Q2 Earnings Expected to Decline
- Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/05/2022
|
Why Veru Stock Plummeted on Monday
- A short-seller makes some worrying accusations against the company.
- 05/02/2022
|
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop
- Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look.
- 05/02/2022
|
5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins
- Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
- 05/02/2022
|
4 Stocks With Solid Financial Strength
- Benjamin Graham, the father of value investing, recommended investors look for stocks that have a current ratio higher than 2 and more working capital than long-term debt.
- 04/27/2022
|
Is Veru Stock a Buy Now?
- Things are looking up with a new drug launch and some great late-stage data.
- 04/21/2022
|
This Hidden Stock Exploded by 190% in a Day. Is It a Buy?
- Its drug for severe COVID-19 could be a smash hit, based on recent clinical trial findings.
- 04/16/2022
|
Why Veru Stock Soared Today
- Wall Street is growing more bullish on the biotech's prospects.
- 04/13/2022
|
Why Veru's Shares Fell 21.8% on Tuesday
- Investors sold on the news that the company said its COVID-19 therapy was safe and effective against all variants.
- 04/12/2022
|
Why Veru May Be Set To Double, Triple In Price And How To Play This Consolidation Pattern
- Veru Inc (NASDAQ: VERU) shot up 235% at one point on Monday before closing the trading session up more than 180% off Friday's closing price. On Tuesday, the stock was consolidating the move higher by setting up an inside bar pattern on the daily chart.
- 04/12/2022
|
Why Veru Stock Skyrocketed Today
- The biotech's experimental COVID-19 treatment could be a game changer.
- 04/11/2022
|
These 8 Stocks Are Seeing Massive Volume Today
- Trading volume is a simple way to measure how much of a security is being traded over a period of time. A high trading volume indicates high buying pressure if the stock is moving higher, or high selling pressure if the stock is moving lower.
- 04/11/2022
|
Why Is Veru (VERU) Stock Up 200% Today?
- Veru (VERU) stock is taking off on Monday as investors react to recent clinical trial news about the company's Covid-19 treatment. The post Why Is Veru (VERU) Stock Up 200% Today?
- 04/11/2022
|
Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients
- Veru Inc (NASDAQ: VERU) has announced positive efficacy and safety results from a planned interim analysis of Phase 3 COVID-19 trial evaluating oral sabizabulin 9 mg versus placebo. The trial included 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress.
- 04/11/2022
|
Why Veru Stock Is Surging Today
- Veru Inc (NASDAQ: VERU) shares are trading significantly higher Monday after the company reported its novel COVID-19 drug candidate reduced deaths by 55% in hospitalized patients in an interim analysis of the Phase 3 study. The study evaluated the company's oral COVID-19 candidate.
- 04/11/2022
|
Pharma Stock Surging on Upbeat Covid-19 Treatment Data
- Another company could be joining the ranks of Covid-19 treatment producers: Veru Inc (NASDAQ:VERU).
- 04/11/2022
|
Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022
- MIAMI, March 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that the Company will present at the Oppenheimer 32nd Annual Healthcare Conference. The presentation will be available through the Conference on March 15, 2022, at 11:20 am Eastern Time.
- 03/01/2022
|
Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call Transcript
- Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call Transcript
- 02/09/2022
|
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
- Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/09/2022
|
Can Veru Inc. (VERU) Climb 344% to Reach the Level Wall Street Analysts Expect?
- The consensus price target hints at a 343.6% upside potential for Veru Inc. (VERU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 02/08/2022
|
Earnings Preview: Veru Inc. (VERU) Q1 Earnings Expected to Decline
- Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/02/2022
|
Veru's Cancer Candidate Sabizabulin Gets FDA Fast Track Tag For COVID-19
- The FDA has granted Fast Track designation to Veru Inc's VERU sabizabulin, oral cytoskeleton disruptor, to combat COVID-19 infection and the cytokine storm responsible for Acute Respiratory Distress Syndrome (ARDS) and death. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
- 01/31/2022
|
Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th
- MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2022 first quarter, on Wednesday, February 9, 2022, before the market opens. Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.
- 01/26/2022
|
Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug
- The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.
- 01/12/2022
|
Why Veru Stock Triumphed on Tuesday
- The company wins Fast Track designation for a top pipeline program.
- 01/11/2022
|
Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022
- MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will present at the H.C. Wainwright BioConnect Conference. The presentation will be available through the Conference from January 10-13, 2022, beginning at 7:00 am Eastern Standard Time on January 10th.
- 01/03/2022
|
Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2021 Results - Earnings Call Transcript
- Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2021 Results - Earnings Call Transcript
- 12/02/2021
|
Veru: Q4 Earnings Insights
- Veru (NASDAQ:VERU) reported its Q4 earnings results on Thursday, December 2, 2021 at 06:30 AM. Here's what investors need to know about the announcement.
- 12/02/2021
|
Earnings Outlook For Veru
- Veru (NASDAQ:VERU) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement.
- 12/01/2021
|
Analysts Estimate Veru Inc. (VERU) to Report a Decline in Earnings: What to Look Out for
- Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/25/2021
|
Veru Inc.: Women's Health, COVID Trial, Oncology Pipeline - 3 Opportunities For The Price Of 1
- Veru Inc. is a rare thing in biotech - a profitable business carrying out 3 pivotal trials for drugs in development targeting oncology and COVID.
- 11/24/2021
|
Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd
- MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2021 fourth quarter and full year ended September 30, 2021, on Thursday, December 2, 2021, before the market opens. Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.
- 11/18/2021
|
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
- -- Enobosarm is a novel targeted hormone drug to be evaluated in the 3 rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed, validated, and used to select patients who are most likely to respond to enobosarm treatment --
- 10/13/2021
|
7 Top-Rated Pharmaceutical Stocks To Invest in for October
- It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first on InvestorPlace.
- 10/04/2021
|
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
- MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111) in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent were presented at the European Society for Medical Oncology (ESMO) Congress 2021 being held September 16-21, 2021. Sabizabulin is a new oral chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt both the cytoskeleton and androgen receptor transport.
- 09/20/2021
|
Veru to Present at Three Upcoming Healthcare Investment Conferences
- MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the following upcoming healthcare investor conferences.
- 09/08/2021
|
Why Veru Stock Vaulted Higher Today
- An analyst raised his price target for the stock.
- 09/02/2021
|
Why Veru Stock Blasted Higher on Friday
- An analyst argues that the company has far more value than many realize.
- 08/27/2021
|
Veru, Inc. (VERU) CEO Mitchell Steiner on Q3 2021 Results - Earnings Call Transcript
- Veru, Inc. (VERU) CEO Mitchell Steiner on Q3 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Veru Stock Gains After Q3 Result Tops Estimates
- Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2 prescription net revenues climbed 150% Y/Y to $13.5 million.
- 08/12/2021
|
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
- Veru Inc. (VERU) delivered earnings and revenue surprises of 50.00% and 26.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter
- --Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs—
- 08/12/2021
|
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress
- MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton disruptor being evaluated for the treatment of metastatic castration resistant prostate cancer in men who progressed on an androgen receptor targeting agent, were accepted for presentation at the European Association of Urology 36th Annual Congress. The Congress is being held virtually from July 8-12, 2021.
- 06/28/2021
|
Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer
- --Sabizabulin is a novel oral androgen receptor transport disruptor-- -- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resistant prostate cancer patients who have also become resistant to abiraterone or enzalutamide, but prior to IV chemotherapy-- --Phase 3 clinical study will be conducted in 45 clinical centers across the United States-- MIAMI, June 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it has enrolled the first patient in its Phase 3 VERACITY clinical trial of sabizabulin, an oral, first-in-class, new chemical entity, androgen receptor transport disruptor (targets and inhibits microtubules to disrupt androgen receptor transport into the nucleus), for metastatic castration and androgen receptor targeting agent resistant prostate cancer.
- 06/25/2021
|
Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer
- --VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --The Phase 2 clinical trial is expected to be completed by 2H calendar 2021--
- 06/10/2021
|
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
- -- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ 40% AR expression in cancer tissue -- -- Companion diagnostic test to measure AR may be used to select AR+ER+HER2- metastatic breast cancer subjects most likely to benefit from enobosarm treatment--
- 06/07/2021
|
Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting
- -- Sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing Phase 1b/2 study of 80 men -- -- Phase 3 VERACITY study to evaluate sabizabulin treatment in men who have metastatic castration prostate cancer and have also progressed following at least one androgen receptor targeting agent planned to start this month --
- 06/07/2021
|
Veru to Present at the Jefferies Virtual Healthcare Conference
- MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference. The presentation will be available through the Conference on Tuesday, June 1st at 8:00 a.m. ET.
- 05/25/2021
|
Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- -- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue -- -- Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer --
- 05/24/2021
|
Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients
- —Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities—
- 05/19/2021
|
Veru, Inc. (VERU) CEO Mitchell Steiner on Q2 2021 Results - Earnings Call Transcript
- Veru, Inc. (VERU) CEO Mitchell Steiner on Q2 2021 Results - Earnings Call Transcript
- 05/12/2021
|
Veru: Q2 Earnings Insights
- Shares of Veru (NASDAQ:VERU) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share fell 300.00% over the past year to ($0.04), which were in line with the estimate of ($0.04).
- 05/12/2021
|
Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues
- -- First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients-- --New Drug Application Accepted for Review by FDA for Proprietary TADFIN Daily Oral Dosing Combination for BPH; PDUFA Date December 2021--
- 05/12/2021
|
VERU Stock: From $8.70 To $10.43 (19.89% Increase) Pre-Market Explanation
- The stock price of Veru Inc (NASDAQ: VERU) increased from $8.70 to $10.43 pre-market. This is why it happened.
- 05/05/2021
|
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
- MIAMI, May 05, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the clinical results from the Phase 2 clinical study of enobosarm, an oral selective androgen receptor targeting agonist, in heavily pretreated women with AR+ER+HER2- advanced breast cancer including further efficacy data and an analysis of patients who have failed both estrogen blocking agents and CDK 4/6 inhibitors, will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 to be held May 05-08, 2021.
- 05/05/2021
|
Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
- MIAMI, April 21, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that clinical results from the Phase 2 clinical study of enobosarm, a selective androgen receptor targeting agonist, in heavily pretreated women with AR+ER+HER2- advanced breast cancer including further efficacy data and an analysis of patients who have failed both estrogen blocking agents and CDK 4/6 inhibitors, has been accepted for a poster presentation at the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 to be held May 05-08, 2021. Enobosarm is an oral, first-in-class, selective androgen receptor targeting agonist that activates the androgen receptor, a tumor suppressor, in AR+ER+HER2- metastatic breast cancer. The planned Phase 3 ARTEST study will evaluate enobosarm monotherapy versus an active control (exemestane or SERM) for the treatment of metastatic AR+ER+HER2- breast cancer patients whose disease has progressed after treatment with a nonsteroidal aromatase inhibitor (anastrozole or letrozole), fulvestrant, and a CDK 4/6 inhibitor and the study is anticipated to commence in Q2 2021.
- 04/21/2021
|
Are Options Traders Betting on a Big Move in Veru (VERU) Stock?
- Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
- 04/05/2021
|
Veru to Present at the Oppenheimer 31st Annual Healthcare Conference
- MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference. The presentation will be available through the Conference on Tuesday, March 16th at 3:10 p.m. ET.
- 03/09/2021
|
Veru mulls selling female health business
- Shares of Veru Inc. gained 6.5% in trading on Monday after the company said it is considering selling its female condom product. Veru hired Morgan Stanley & Co. as its financial advisor, saying the female condom business was no longer a strategic fit for the company now that it is advancing oncology and COVID-19 products through clinical trials.
- 03/08/2021
|
Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference
- MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The fireside chat will be available on-demand through the Conference on March 9th, 2021 starting at 7 a.m. ET.
- 03/02/2021
|
Veru (VERU) Reports Q1 Loss, Tops Revenue Estimates (Revised)
- Veru (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Veru's VERU-111 Moves Into Pivotal COVID-19 Study
- Veru Inc (NASDAQ: VERU) will start testing VERU-111 in the registrational Phase 3 study in hospitalized patients who have COVID-19 virus infection and are at high risk for Acute Respiratory Distress Syndrome. Mitchell Steiner, chairman, president, and CEO, said, "we have the resources to conduct a Phase 3 trial without impacting our cancer drugs' clinical development.
- 03/01/2021
|
Veru Submits New Drug Application for Proprietary TADFIN for BPH
- --TADFIN™, Tadalafil 5mg and Finasteride 5mg formulated capsule, for daily oral dosing to improve compliance-- --Administration of Tadalafil and Finasteride is more effective than Finasteride alone to treat symptoms of benign prostatic hyperplasia--
- 02/23/2021
|
Why Veru, Invitae And More Are Moving Today
- Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospital operator in the United States.
- 02/18/2021
|
Veru Raises $100M Via Equity At 10% Discount
- Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 967,741 shares.
- 02/18/2021
|
Veru Announces Pricing of Public Offering of Common Stock
- MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today the pricing of an underwritten public offering of 6,451,613 shares of its common stock at a price to the public of $15.50 per share. The gross proceeds to Veru from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $100 million. In addition, Veru has granted the underwriters a 30-day option to purchase up to an additional 967,741 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about February 22, 2021, subject to the satisfaction of customary closing conditions.
- 02/17/2021
|
Veru Announces Proposed Public Offering of Common Stock
- MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Veru intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 02/17/2021
|
Veru, Inc. (VERU) CEO Mitchell Steiner on Q1 2021 Results - Earnings Call Transcript
- Veru, Inc. (VERU) CEO Mitchell Steiner on Q1 2021 Results - Earnings Call Transcript
- 02/10/2021
|
Female Health Company The (VERU) Reports Q1 Loss, Tops Revenue Estimates
- Female Health Company The (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/10/2021
|
Recap: Veru Q1 Earnings
- Shares of Veru (NASDAQ:VERU) moved higher by 17.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year over year to ($0.02), which beat the estimate of ($0.06).
- 02/10/2021
|
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter
- --Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter-- --Late Clinical Stage Oncology Drug Pipeline Focused on Prostate and Breast Cancers Continues to Advance to Registration Phase 3 Clinical Studies--
- 02/10/2021
|
Why Veru Stock Surged Today
- Analysts are excited about the potential of the biotech's experimental COVID-19 treatment.
- 02/09/2021
|
Veru reports cancer drug has high potential to reduce Covid-19 deaths
- Dr. Mitchell Steiner, chief executive of drugmaker Veru, said a Phase 2 trial of VERU-111 showed an 82% relative reduction in Covid-19 patient mortality versus placebo.
- 02/08/2021
|
Veru CEO says cancer drug has potential to prevent Covid-19 deaths
- Veru CEO Dr. Mitchell Steiner explained how VERU-111, a prostate cancer drug developed by the biotech company, could be used as an anti-inflammatory and antiviral treatment to help patients diagnosed with the novel coronavirus.
- 02/08/2021
|
Why Veru Stock Is Skyrocketing Today
- The company reported great results from a phase 2 study in treating hospitalized COVID-19 patients.
- 02/08/2021
|
VERU Stock Price Increases Over 20% Pre-Market: Why It Happened
- The stock price of Veru Inc (NASDAQ: VERU) is trading at over 20% pre-market. This is why it happened.
- 02/08/2021
|
Veru's COVID-19 Drug Candidate Shows High Relative Reduction In Treatment Failures, Mortality In Mid-Stage Study
- Veru Inc (NASDAQ: VERU) rises sharply after announcing positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in approximately 40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome from SARS-CoV-2. Data showed that VERU-111 treatment compared to placebo had a statistically significant and clinically meaningful reduction in the proportion of treatment failures with a 30% treatment failure rate in the placebo group compared to a 5.6% in the VERU-111 treated group at Day 29.
- 02/08/2021
|
Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
- – Potential for two-pronged action against COVID-19 as an antiviral and anti-inflammatory agent supported by Phase 2 clinical study results –
- 02/08/2021
|
Will Female Health Company The (VERU) Report Negative Earnings Next Week? What You Should Know
- Female Health Company The (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/03/2021
|
Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10th
- MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 first quarter ended December 31, 2020, on Wednesday, February 10, 2021 before the market opens. Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.
- 01/27/2021
|
Is The Rally In Veru Overdone?
- After a stellar 3x rise since the March 23 levels of last year, at the current price of around $10 per share we believe Veru Inc. stock, a biopharmaceuticals company focused on oncology medicines, has reached its near-term potential. Veru stock has rallied from $3 to $10, significantly.
- 01/12/2021
|
Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021
- MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the H.C. Wainwright Bioconnect 2021 Conference. The presentation will be available on-demand through the Conference from January 11-14, 2021 starting at 6:00 a.m. ET.
- 01/04/2021
|
Implied Volatility Surging for Veru (VERU) Stock Options
- Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
- 12/15/2020
|
Veru's stock soars again on heavy volume after positive results of breast cancer treatment
- Shares of Veru Inc. soared 51.4% toward a seven-year high on massive volume, after the biopharmaceutical company announced positive results from a Phase 2 study of its treatment of breast cancer. Trading volume was 105 million shares, enough to make the stock the most actively traded on the Nasdaq exchange.
- 12/14/2020
|
5 Biopharma Stocks Making Big Moves Monday
- Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific updates. Arvinas Inc (NASDAQ: ARVN): The smid-cap biopharma announced clinical program updates for its protein degraders ARV-471 and ARV-110.
- 12/14/2020
|
VERU Stock News: 9 Things for Investors to Know About Veru Breast Cancer Trial Results
- Veru (VERU) stock is doing well on Monday after announcing positive news from a Phase 2 clinical trial of its breast cancer drug. The post VERU Stock News: 9 Things for Investors to Know About Veru Breast Cancer Trial Results appeared first on InvestorPlace.
- 12/14/2020
|
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
- -- Phase 2 Multicenter, International Clinical Study Selected as Spotlight Presentation at 2020 San Antonio Breast Cancer Symposium –
- 12/14/2020
|
VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
- -- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors-- --Veru Plans to Meet with FDA and Advance VERU-111 into a Phase 2b Clinical Trial in Women with Paclitaxel Resistant Triple Negative Breast Cancer in 2021--
- 12/14/2020
|
Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call Transcript
- Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call Transcript
- 12/09/2020
|
Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer
- -- Transformation to P remium O ncology B iopharmaceutical C ompany with L ate - S tage Clinical Drug P ipeline F ocused on P rostate and B reast C ancer is C omplete -- -- Company Poised to Initiate Four Oncology Drug Registration Trials i n Prostate and Breast Cancer in Calendar Year 2021 --
- 12/09/2020
|
Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results
- —FY20 Full-Year Net Revenue s and Gross Profit Achieve Historical Highs o f $4 3 M illion and $ 31 M illion , Respectively—
- 12/09/2020
|
Preview: Veru's Earnings
- Veru (NASDAQ:VERU) releases its next round of earnings this Wednesday, December 09. Here is Benzinga's essential guide to Veru's Q4 earnings report.
- 12/08/2020
|
Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th
- MIAMI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 fourth quarter and full year ended September 30, 2020, on Wednesday, December 9, 2020, before the market opens. Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.
- 11/23/2020
|
